✦ LIBER ✦

57 Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy

✍ Scribed by X. Qi; A. Snow; V. Thibault; Y. Zhu; M. Curtis; S.J. Hadziyannis; C.L. Brosgart; G. Currie; S. Arterburn; C.S. Gibbs; M.D. Miller; S. Xiong

Book ID: 117372887
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 59 KB
Volume: 40
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(04)90057-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Resistance profile of adefovir dipivoxil

Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy

✍ C.E. Westland; H. Yang; W.E. Delaney IV; V. Thibault; Y. Benhamou; C.S. Gibbs; M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 162 KB

36 Incidence and predictors of emergence

36 Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 108 KB

18 OUTCOME OF HBeAg-NEGATIVE CHRONIC HEP

18 OUTCOME OF HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHB) 5 YEARS AFTER DISCONTINUATION OF LONG TERM ADEFOVIR DIPIVOXIL (ADV) TREATMENT

✍ S. Hadziyannis; V. Sevastianos; I. Rapti 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 70 KB

W1813 Incidences of Renal Dysfunction in

W1813 Incidences of Renal Dysfunction in Chronic Hepatitis B (CHB) Patients Treated with Adefovir Dipivoxil (ADV) 10mg

✍ Ha, Nghi B.; Ha, Nghiem B.; Garcia, Ruel T.; Trinh, Huy N.; Wan, Kenton; Nguyen, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Increased risk of adefovir resistance in

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy

✍ Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu L 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood. We compared the emergence of the ADV-resistant mutations rt

Long-term safety beyond 48 weeks of adef

Long-term safety beyond 48 weeks of adefovir dipivoxil (ADV) 10 Mg once daily for chronic hepatitis B (CHB): An integrated analysis of two phase III studies

✍ Tong, M.; Shiffman, M.; Heathcote, J.; Gish, R.; Jeffers, L.; Sacks, S.; Kaita, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 252 KB